PRRT Clinical Trial Update – PMH Site
On October 2, 2016, CNETS Canada held a Toronto Patient Education Day entitled PRRT Clinical Trial Update – PMH Site, with presentations by Dr. Rebecca Wong and Dr. Shereen Ezzat. [...]
ESMO 2016 NET News
Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced [...]
Survey on the Canadian NET Cancer Patient Experience with the Gallium 68 Scan
CNETS Canada is looking to gain insight into the Canadian neuroendocrine (NET) cancer patient experience with Gallium 68 scans to date. This information will assist us in developing next steps [...]
2016 Maureen Coleman Award – We Need Your Submissions!
One way that CNETS Canada honours those individuals who have made an outstanding commitment and contribution to the NET cancer patient community is through our annual Maureen Coleman award. Maureen [...]
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors (PET/Ga68) Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE [...]
First Global Neuroendocrine Tumor Patient Survey Results
“Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” – a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and [...]
Date changes – Brampton and Toronto Support Groups
After review of the results of our recently conducted patient support survey and based on input from our local communities and our local Support Group Leaders, we are implementing the [...]
New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors Not yet [...]
Patient Survey: pCODR Patient Advocacy Group Input on a Drug Review for Everolimus (Afinitor): Indication for Gastrointestinal and Lung Neuroendocrine Tumours
The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours. Everolimus is a cancer medicine that [...]
PRRT clinical trial at CHU de Québec
We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called: Personalized Peptide Receptor Radionuclide Therapy of [...]